secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001159036-22-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).
- FY22 guidance raised: total revenue $655-685M (prior $530-560M); non-GAAP EPS $2.10-2.25.
- Antares Pharma acquisition closed May 2022; expected to add $115-125M revenue in FY22.
- Operating income $34.1M vs $93.0M in Q2 2021, reflecting Antares-related transaction costs.
- Cash and marketable securities $209.4M on June 30, 2022, down from $740.9M at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/0001159036-22-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/halo-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001159036-22-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer